Also trades as: 0RC7.L (LSE) · $vol 0M
HNSA.ST STO
Hansa Biopharma AB (publ)
1W: +2.5%
1M: -25.4%
3M: -4.0%
YTD: -10.3%
1Y: +5.9%
3Y: -26.6%
5Y: -73.0%
kr 33.18 ($3.30)
-0.94 (-2.75%)
Weekly Expected Move ±6.2%
kr 29
kr 31
kr 33
kr 35
kr 37
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$549M
+18.6% ▲
Capital Expenditures
$0
+100.0% ▲
Free Cash Flow
-$549M
+18.6% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$296M
+190.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$548M | -$611M | -$832M | -$807M | -$529M |
| Depreciation & Amort. | $9M | $12M | $20M | $0 | $0 |
| Stock-Based Comp. | $57M | $58M | $0 | $0 | $0 |
| Change in Working Capital | $3M | $21M | $11M | -$64M | -$38M |
| Other Non-Cash Items | $56M | $75M | $45M | $196M | $18M |
| Operating Cash Flow | -$481M | -$503M | -$756M | -$675M | -$549M |
| — Investing Activities — | |||||
| Capital Expenditures | -$2M | -$3M | -$284K | -$116K | $0 |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $233M | $0 | $0 | $0 |
| Other Investing | $0 | $233M | $0 | $0 | $0 |
| Investing Cash Flow | -$2M | $229M | -$284K | -$116K | $0 |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $728M | $0 | -$8M | -$10M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$5M | -$7M | -$8M | $0 | $10M |
| Financing Cash Flow | -$5M | $1.1B | -$8M | $347M | $848M |
| Net Change in Cash | -$488M | $845M | -$764M | -$327M | $296M |
| Cash End of Period | $651M | $1.5B | $732M | $405M | $701M |
| Free Cash Flow | -$484M | -$506M | -$756M | -$675M | -$549M |